Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma

Summary

A multicentric, open-label, single-arm prospective study to assess the efficacy and safety of tislelizumab combined with TACE as first-line treatment in patients with unresectable BCLC stage C HCC.

Timeline

Start

2020-10-27

Primary completion

2022-11

Completion

2023-11

Drugs

Indications